Icosapent (MND-2119)
MND2119H31
Phase 3 small_molecule completed
Quick answer
Icosapent (MND-2119) for Hypertriglyceridemia is a Phase 3 program (small_molecule) at Mochida Pharmaceutical Company, with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Mochida Pharmaceutical Company,
- Indication
- Hypertriglyceridemia
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed